Hongjun Bai

Mar 11, 2024 | nature.com | Craig A Magaret |Allan C. deCamp |Morgane Rolland |Michal Juraska |Brian Williamson |James Ludwig | +23 more

AbstractIn the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs.

Nov 19, 2023 | biorxiv.org | Hongjun Bai |Eric Lewitus |Yifan Li |Vincent Dussupt

AbstractAn effective HIV-1 vaccine must elicit broadly neutralizing antibodies (bnAbs) against the highly diverse Envelope glycoproteins (Env) present globally. Since Env with the longest hypervariable (HV) loops were more resistant to the cognate bnAbs than Env with shorter HV loops, we redesigned hypervariable loops for updated HIV-1 Env consensus sequences of subtypes B and C and circulating recombinant form AE (CRF01_AE).